{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:50:52Z","timestamp":1786996252667,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.reuma.2020.04.015","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T07:39:08Z","timestamp":1592638748000},"page":"504-513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Revisi\u00f3n sistem\u00e1tica sobre el impacto de los f\u00e1rmacos en la enfermedad pulmonar intersticial difusa asociada a Artritis Reumatoide"],"prefix":"10.1016","volume":"17","author":[{"given":"Carmen","family":"Carrasco Cubero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Chamizo Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Vela Casasempere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2020.04.015_bib0265","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1093\/rheumatology\/keq035","article-title":"Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort","volume":"49","author":"Koduri","year":"2010","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reuma.2020.04.015_bib0270","year":"2017","journal-title":"Gu\u00eda de Pr\u00e1ctica Cl\u00ednica para el manejo de la Artritis Reumatoide en Espa\u00f1a"},{"key":"10.1016\/j.reuma.2020.04.015_bib0275","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheumatism."},{"key":"10.1016\/j.reuma.2020.04.015_bib0280","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1378\/chest.127.6.2019","article-title":"Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease","volume":"127","author":"Lee","year":"2005","journal-title":"Chest."},{"key":"10.1016\/j.reuma.2020.04.015_bib0285","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4046\/trd.2019.0009","article-title":"Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 5. Connective Tissue Disease Associated Interstitial Lung Disease","volume":"82","author":"Koo","year":"2019","journal-title":"Tuberc Respir Dis"},{"key":"10.1016\/j.reuma.2020.04.015_bib0290","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1183\/13993003.00357-2015","article-title":"Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease","volume":"47","author":"Solomon","year":"2016","journal-title":"European Respiratory Journal."},{"key":"10.1016\/j.reuma.2020.04.015_bib0295","unstructured":"L\u00f3pez de Argumedo M, Reviriego E, Guti\u00e9rrez A, Bay\u00f3n JC. Actualizaci\u00f3n del Sistema de Trabajo Compartido para Revisiones Sistem\u00e1ticas de la Evidencia Cient\u00edfica y Lectura Cr\u00edtica (P lataforma FLC 3.0). In: OSTEBA. SdEdTSdPVIdEdTS, editor. 2017."},{"key":"10.1016\/j.reuma.2020.04.015_bib0300","unstructured":"Network. SIG. SIGN 50, A guideline developer's handbook. 2011."},{"key":"10.1016\/j.reuma.2020.04.015_bib0305","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4236\/ojra.2012.23011","article-title":"Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia","volume":"2","author":"Matteson","year":"2012","journal-title":"Open Journal of Rheumatology and Autoimmune Diseases."},{"key":"10.1016\/j.reuma.2020.04.015_bib0310","first-page":"1","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","author":"Flaherty","year":"2019","journal-title":"New Engl J Med."},{"key":"10.1016\/j.reuma.2020.04.015_bib0315","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/art.38322","article-title":"Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"66","author":"Conway","year":"2014","journal-title":"Arthritis & rheumatology (Hoboken, NJ)."},{"key":"10.1016\/j.reuma.2020.04.015_bib0320","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3899\/jrheum.150674","article-title":"Leflunomide Use and Risk of Lung Disease in Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials","volume":"43","author":"Conway","year":"2016","journal-title":"The Journal of rheumatology."},{"key":"10.1016\/j.reuma.2020.04.015_bib0325","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.2147\/DDDT.S204730","article-title":"Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon?","volume":"13","author":"Huang","year":"2019","journal-title":"Drug design, development and therapy."},{"key":"10.1016\/j.reuma.2020.04.015_bib0330","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/annrheumdis-2015-eular.2004","article-title":"Abatacept and its impact on interstitial lung disease: A systematic literature review","volume":"74","author":"Nelson","year":"2015","journal-title":"Annals of the rheumatic diseases."},{"key":"10.1016\/j.reuma.2020.04.015_bib0335","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1093\/rheumatology\/ker289","article-title":"Non-infectious pulmonary complications of newer biologic agents for rheumatic diseases a systematic literature review","volume":"50","author":"Hadjinicolaou","year":"2011","journal-title":"Rheumatology."},{"key":"10.1016\/j.reuma.2020.04.015_bib0340","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","article-title":"Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review","volume":"43","author":"Roubille","year":"2014","journal-title":"Seminars in arthritis and rheumatism."},{"key":"10.1016\/j.reuma.2020.04.015_bib0345","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","article-title":"Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases","volume":"41","author":"P\u00e9rez-\u00c1lvarez","year":"2011","journal-title":"Seminars in arthritis and rheumatism."},{"key":"10.1016\/j.reuma.2020.04.015_bib0350","doi-asserted-by":"crossref","first-page":"e028466","DOI":"10.1136\/bmjopen-2018-028466","article-title":"Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts","volume":"9","author":"Kiely","year":"2019","journal-title":"BMJ open."},{"key":"10.1016\/j.reuma.2020.04.015_bib0355","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.reuma.2011.12.008","article-title":"Interstitial lung disease related to rheumatoid arthritis: evolution after treatment","volume":"8","author":"Rojas-Serrano","year":"2012","journal-title":"Reumatologia clinica."},{"key":"10.1016\/j.reuma.2020.04.015_bib0360","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10067-017-3707-5","article-title":"Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis","volume":"36","author":"Rojas-Serrano","year":"2017","journal-title":"Clinical rheumatology."},{"key":"10.1016\/j.reuma.2020.04.015_bib0365","first-page":"43","article-title":"Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF-alpha agents","volume":"35","author":"Detorakis","year":"2017","journal-title":"Clinical and experimental rheumatology."},{"key":"10.1016\/j.reuma.2020.04.015_bib0370","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2009.120626","article-title":"Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register","volume":"69","author":"Dixon","year":"2010","journal-title":"Annals of the rheumatic diseases."},{"key":"10.1016\/j.reuma.2020.04.015_bib0375","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/14397595.2016.1173816","article-title":"Efficacy of intensive immunosuppression in exacerbated rheumatoid arthritis-associated interstitial lung disease","volume":"27","author":"Ota","year":"2017","journal-title":"Modern rheumatology."},{"key":"10.1016\/j.reuma.2020.04.015_bib0380","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J Rheumatology."},{"issue":"Supp1","key":"10.1016\/j.reuma.2020.04.015_bib0385","first-page":"i99","article-title":"The effect of steroids, azathiprine and mycophenolate on the risk of death in rheumatoid lung disease","volume":"55","author":"Kelly","year":"2016","journal-title":"Rheumatology (Oxford, England)."},{"key":"10.1016\/j.reuma.2020.04.015_bib0390","first-page":"73","article-title":"Association between steroid therapy and survival in patients with rheumatoid arthritis interstitial lung disease","author":"Scott","year":"2014","journal-title":"Annals of the rheumatic diseases."},{"key":"10.1016\/j.reuma.2020.04.015_bib0395","doi-asserted-by":"crossref","first-page":"e000473","DOI":"10.1136\/rmdopen-2017-000473","article-title":"Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic","volume":"3","author":"Druce","year":"2017","journal-title":"RMD open."},{"key":"10.1016\/j.reuma.2020.04.015_bib0400","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13075-015-0835-7","article-title":"Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor alpha agents, a retrospective cohort study","volume":"17","author":"Curtis","year":"2015","journal-title":"Arthritis research & therapy."},{"key":"10.1016\/j.reuma.2020.04.015_bib0405","doi-asserted-by":"crossref","first-page":"e005615","DOI":"10.1136\/bmjopen-2014-005615","article-title":"Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis","volume":"4","author":"Nakashita","year":"2014","journal-title":"BMJ open."},{"issue":"Suppl 10","key":"10.1016\/j.reuma.2020.04.015_bib0410","first-page":"S573","article-title":"The Incidence of Exacerbation of Pre-Existing Interstitial Lung Disease (ILD) Is Higher in TNF Blockers Than in Non-TNF Blockers in RA","volume":"62","author":"Nakashita","year":"2012","journal-title":"Arthritis & rheumatology."},{"key":"10.1016\/j.reuma.2020.04.015_bib0415","doi-asserted-by":"crossref","first-page":"i44","DOI":"10.1093\/rheumatology\/keu091.006","article-title":"Rheumatoid-arthritis-related interstitial lung disease: Association between biologic therapy and survival","volume":"53","author":"Palmer","year":"2014","journal-title":"Rheumatology (United Kingdom)."},{"key":"10.1016\/j.reuma.2020.04.015_bib0420","first-page":"402","article-title":"Pulmonary function in patients with rheumatoid arthritis treated with anti-TNF biologic agents","volume":"62","author":"Odden","year":"2010","journal-title":"Arthritis and rheumatism."},{"key":"10.1016\/j.reuma.2020.04.015_bib0425","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3904\/kjim.2015.30.1.104","article-title":"Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent","volume":"30","author":"Koo","year":"2015","journal-title":"Korean J Intern Medicine"},{"issue":"Suppl 1","key":"10.1016\/j.reuma.2020.04.015_bib0430","first-page":"i86","article-title":"Efficacy and Safety of Rituximab in Rheumatoid Arthritis Patients with Concomitant Interstitial Lung Disease: 10-Year Experience at Single Centre","volume":"54","author":"Kabia","year":"2015","journal-title":"Rheumatology."},{"key":"10.1016\/j.reuma.2020.04.015_bib0435","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.resinv.2016.03.001","article-title":"Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients","volume":"54","author":"Nakashita","year":"2016","journal-title":"Respiratory investigation."},{"key":"10.1016\/j.reuma.2020.04.015_bib0440","first-page":"1","article-title":"A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease","author":"Li","year":"2019","journal-title":"Clinical rheumatology."},{"key":"10.1016\/j.reuma.2020.04.015_bib0445","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.21806","article-title":"Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis","volume":"54","author":"Suissa","year":"2006","journal-title":"Arthritis and rheumatism."},{"key":"10.1016\/j.reuma.2020.04.015_bib0450","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","year":"2012","journal-title":"New England Journal of Medicine."},{"key":"10.1016\/j.reuma.2020.04.015_bib0455","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.pupt.2011.01.016","article-title":"Tacrolimus-induced pulmonary injury in rheumatoid arthritis patients","volume":"24","author":"Koike","year":"2011","journal-title":"Pulmonary pharmacology & therapeutics."},{"issue":"Suppl III","key":"10.1016\/j.reuma.2020.04.015_bib0460","first-page":"470","article-title":"Inflammatory intersticial lung disease in rheumatoid arthritis patients treated with biologic treatment. Incidence and mortality rates compared with patients non receiving biologics","volume":"64","author":"Garc\u00eda-Vicu\u00f1a","year":"2005","journal-title":"Annals of the rheumatic diseases."},{"key":"10.1016\/j.reuma.2020.04.015_bib0465","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.130466","article-title":"Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan","volume":"41","author":"Koike","year":"2014","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2020.04.015_bib0470","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/resp.13419_192","article-title":"Effect of tocilizumab on interstitial lung disease in patients with rheumatoid arthritis","volume":"23","author":"Otsuji","year":"2018","journal-title":"Respirology (Carlton, Vic)."},{"key":"10.1016\/j.reuma.2020.04.015_bib0475","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/art.21758","article-title":"Morphologic and quantitative assessment of CD20+B cell infiltrates in rheumatoid arthritis\u2013associated nonspecific interstitial pneumonia and usual interstitial pneumonia","volume":"54","author":"Atkins","year":"2006","journal-title":"Arthritis & Rheumatism."},{"key":"10.1016\/j.reuma.2020.04.015_bib0480","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years\u2019 experience at a single centre","volume":"56","author":"Md Yusof","year":"2017","journal-title":"Rheumatology (Oxford, England)."},{"key":"10.1016\/j.reuma.2020.04.015_bib0485","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s10067-019-04557-7","article-title":"Rituximab in connective tissue disease-associated interstitial lung disease","volume":"38","author":"Duarte","year":"2019","journal-title":"Clinical rheumatology."},{"key":"10.1016\/j.reuma.2020.04.015_bib0490","article-title":"Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis","author":"Fui","year":"2019","journal-title":"Internal medicine journal."},{"key":"10.1016\/j.reuma.2020.04.015_bib0495","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semarthrit.2017.12.012","article-title":"Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients","volume":"48","author":"Fern\u00e1ndez-D\u00edaz","year":"2018","journal-title":"Seminars in arthritis and rheumatism."},{"key":"10.1016\/j.reuma.2020.04.015_bib0500","first-page":"164","article-title":"Abatacept en enfermedad pulmonar intersticial asociada a artritis reumatoide Estudio multic\u00e9ntrico en 181 pacientes","volume":"15","author":"Fern\u00e1ndez D\u00edaz","year":"2019","journal-title":"Reumatolog\u00eda cl\u00ednica."},{"key":"10.1016\/j.reuma.2020.04.015_bib0505","first-page":"1703","article-title":"Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis. Internal medicine (Tokyo","volume":"58","author":"Kurata","year":"2019","journal-title":"Japan)."},{"key":"10.1016\/j.reuma.2020.04.015_bib0510","first-page":"1","article-title":"Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan","author":"Mimori","year":"2016","journal-title":"Modern rheumatology."},{"key":"10.1016\/j.reuma.2020.04.015_bib0515","article-title":"Inhibidor de Janus quinasas como opci\u00f3n terap\u00e9utica en artritis reumatoide y enfermedad pulmonar intersticial asociada: reporte de 4 casos","author":"Saldarriaga-Rivera","year":"2018","journal-title":"Rev Colomb Reumatol."},{"key":"10.1016\/j.reuma.2020.04.015_bib0520","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1007\/s10067-019-04720-0","article-title":"Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases","volume":"38","author":"Fischer","year":"2019","journal-title":"Clinical rheumatology."}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X2030111X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X2030111X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:01:53Z","timestamp":1761663713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X2030111X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1699258X2030111X"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2020.04.015","relation":{},"ISSN":["1699-258X"],"issn-type":[{"value":"1699-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisi\u00f3n sistem\u00e1tica sobre el impacto de los f\u00e1rmacos en la enfermedad pulmonar intersticial difusa asociada a Artritis Reumatoide","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2020.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}